Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ)
CNY21.90
+0.94 (+4.48%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Huangyan Jiangkou Chemical Dev Zn 318020
Taizhou, CN
Taizhou, CN
CEO
Yong Jun Tu
Website
tianyupharm.com
IPO
2017-09-19
ISIN CNE1000034X1
Description
Zhejiang Tianyu Pharmaceutical Co., Ltd. is a global enterprise specializing in the entire lifecycle, from the innovation to the commercialization, of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). The company provides essential chemical building blocks for drugs targeting a diverse range of medical conditions, including cardiovascular disorders, diabetes, anti-atherosclerosis, blood coagulation issues, and asthma. In addition to its primary focus, the firm also delivers specialty chemicals and extends its services to include contract manufacturing (CMO) for other pharmaceutical entities. This Taizhou, China-based company was established in 1993.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY21.90
+0.94 (+4.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.39
Float Shares
253.70M
Free Float %
72.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -3.85% | -8.82% | -23.11% | -25.67% | -18.52% | -15.17% | -26.49% | -48.56% | +59.98% | +59.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
21.90
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.48
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+16.4% ★ Q1'26: +6.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+156.3% ★ Q1'26: -52.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1.0% Q1'26: +9.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.6% Q1'26: +6.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.7% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.5% ★ Q1'26: +1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.97× Q1'26: 7.48× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.19B
est: 1.30B (-8.4%)
|
1.47B
est: 1.47B (0.0%)
|
2.11B
est: 2.15B (-1.9%)
|
2.59B
est: 2.70B (-4.2%)
|
2.55B
est: 2.62B (-3.0%)
|
2.67B
est: 2.91B (-8.4%)
|
2.53B
est: 2.63B (-3.9%)
|
2.63B
est: 2.71B (-2.9%)
|
3.06B
est: 3.11B (-1.7%)
|
3.65B
3.58B – 3.72B
+17.2% YoY
|
4.44B
4.39B – 4.48B
+21.6% YoY
|
5.35B
5.27B – 5.42B
+20.4% YoY
|
| EBITDA |
232.76M
est: 227.37M (+2.4%)
|
298.33M
est: 257.18M (+16.0%)
|
777.66M
est: 377.23M (+106.2%)
|
855.50M
est: 473.31M (+80.7%)
|
371.04M
est: 459.92M (-19.3%)
|
164.56M
est: 510.50M (-67.8%)
|
439.74M
est: 460.89M (-4.6%)
|
432.50M
est: 395.07M (+9.5%)
|
559.79M
est: 453.88M (+23.3%)
|
532.00M
522.12M – 541.88M
+17.2% YoY
|
646.85M
640.39M – 653.32M
+21.6% YoY
|
779.05M
768.22M – 789.88M
+20.4% YoY
|
| EBIT |
156.30M
est: 109.27M (+43.0%)
|
215.54M
est: 123.59M (+74.4%)
|
676.48M
est: 181.28M (+273.2%)
|
719.41M
est: 227.45M (+216.3%)
|
185.84M
est: 221.02M (-15.9%)
|
-79.67M
est: 245.32M (-132.5%)
|
146.09M
est: 221.48M (-34.0%)
|
111.10M
est: 113.35M (-2.0%)
|
201.73M
est: 130.22M (+54.9%)
|
152.63M
149.80M – 155.47M
+17.2% YoY
|
185.58M
183.73M – 187.44M
+21.6% YoY
|
223.51M
220.41M – 226.62M
+20.4% YoY
|
| Net Income |
100.18M
est: 158.84M (-36.9%)
|
163.66M
est: 179.65M (-8.9%)
|
585.73M
est: 621.50M (-5.8%)
|
667.06M
est: 774.93M (-13.9%)
|
204.68M
est: 249.96M (-18.1%)
|
-118.87M
est: 108.37M (-209.7%)
|
27.36M
est: 115.37M (-76.3%)
|
55.94M
est: 107.34M (-47.9%)
|
139.71M
est: 54.52M (+156.3%)
|
318.00M
274.72M – 331.84M
+483.3% YoY
|
402.10M
391.79M – 412.41M
+26.4% YoY
|
500.92M
491.87M – 509.98M
+24.6% YoY
|
| SGA |
204.67M
est: 217.85M (-6.1%)
|
263.87M
est: 246.41M (+7.1%)
|
322.68M
est: 361.43M (-10.7%)
|
361.41M
est: 453.49M (-20.3%)
|
465.02M
est: 440.66M (+5.5%)
|
423.79M
est: 489.12M (-13.4%)
|
425.45M
est: 441.59M (-3.7%)
|
500.32M
est: 419.29M (+19.3%)
|
224.38M
est: 481.71M (-53.4%)
|
564.62M
554.14M – 575.11M
+17.2% YoY
|
686.52M
679.65M – 693.39M
+21.6% YoY
|
826.83M
815.33M – 838.32M
+20.4% YoY
|
| EPS |
0.38
est: 0.45 (-16.4%)
|
0.51
est: 0.51 (-1.7%)
|
1.81
est: 1.78 (+1.8%)
|
2.06
est: 2.22 (-7.1%)
|
0.59
est: 0.72 (-17.5%)
|
-0.34
est: 0.31 (-211.0%)
|
0.08
est: 0.33 (-75.8%)
|
0.16
est: 0.32 (-49.2%)
|
0.41
est: 0.16 (+156.3%)
|
0.89
0.81 – 0.97
+456.3% YoY
|
1.18
1.15 – 1.21
+32.6% YoY
|
1.47
1.44 – 1.50
+24.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
598.54M
OE per share TTM
1.74
Owner's Yield
8.94%
Maintenance CapEx ratio
11.89%
Maint CapEx / Avg PPE
91.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 70.5K | 0.65% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 72.4K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 202.2K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 109.4K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 18.3K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.1K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 900.9K | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 62.2K | 0.28% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 915.9K | 0.05% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 7.4K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
43.0K
Shares Outstanding
347.98M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chuanliang Deng | Deputy GM & Non-Independent Director | — | male |
| Fujun Wang | Deputy General Manager | — | male |
| Guo Rong Zhu | Deputy GM & Non-Independent Director | — | male |
| Xiujuan Wang | Financial Director | — | female |
| Yan Wang | Board Secretary & Deputy GM | — | female |
| Yong Jun Tu | Chairman & GM | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300702.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
